Biochemical Test for Identification of Proteins by Biuret Reagent using Microscale Methods
Review on Evaluation of Therapy Methods Based on Plant Biopharmaceuticals for Covid-19
Factor XI Deficiency and Its Management
Dyslipidemia: Diabetes Lipid Therapies
Pulmonary and Respiratory Health Antioxidants and Nutraceuticals
The Perspective View about Water Hyacinth as Problem or Resource: A Review
Susceptibility of Multidrug Resistant Bacteria to Lyophilized Citrus Limon Juice Extract
The Role of Stilbene Phytoalexins in the Resistance Mechanism of Grapevine Against Plasmopara Viticola
Natural Phyto-Constituents as Leishmanicides: A Brief Review of the Most Widely Recommended Phyto Chemicals of the 21st Century and an Account of their Mode of Action
Neem Root Mediated-Biosynthesis of Silver Nanoparticles: Antimicrobial Activities and Application as Detergent Additive
Diversity Assessment of Insect Species in the Kariavattom Campus, University of Kerala
Obesity: Current Research and Future Hope
A Comprehensive Analysis of Covid-19: An Overview
Dyslipidemia: Diabetes Lipid Therapies
Neem Root Mediated-Biosynthesis of Silver Nanoparticles: Antimicrobial Activities and Application as Detergent Additive
This research paper explores the qualitative analysis of protein samples using the Biuret reagent through microscale methods involving ceramic tiles, groove tiles and Eppendorf tubes. This study highlights the advantages of its minimal reagent usage, reduced waste, and safety enhancements. The Biuret test is employed to detect peptide bonds indicative of protein presence. The microscale adaptation of this traditional test is evaluated for its efficacy, precision, and practicality in various applications, particularly in educational and resource-limited laboratory settings.
Several opportunities to investigate a variety of treatment techniques for the prevention of infection have been presented as a result of the unprecedented COVID-19 pandemic. The development of vaccinations against the coronavirus has been the focus of the efforts of a large number of researchers all around the world. It was of the utmost importance to adequately administer treatment for the illness while searching for suitable antiviral medications. This study effort is to investigate the numerous causes of infections as well as the various treatments that are currently being used. Furthermore, it aims to create therapeutic and preventive options that are derived from plants that can be employed in conjunction with the therapy of COVID-19.
Factor XI deficiency, also called hemophilia C, is an unprecedented bleeding ailment due to inadequate levels of coagulation component XI, a critical protein in the intrinsic pathway of blood clotting. In contrast to hemophilia A and B, which contain deficiencies in elements VIII and IX, aspect XI deficiency usually results in milder bleeding. Management of XI deficiency requires a comprehensive technique that considers the severity of bleeding episodes, patient responses, and potential dangers. Treatment options consist of an aspect replacement remedy, desmopressin (DDAVP), and antifibrinolytic pills tailored to fulfill every patient's precise needs. Aspect substitute remedies include administering plasma-derived or recombinant element XI concentrates on raising poor ranges and effectively preventing and treating bleeding events. However, challenges exist because of the limited availability of XI concentrates. DDAVP, a synthetic hormone, stimulates the discharge of stored factor XI from endothelial cells and quickly increases clotting levels. Although effective in a few instances, not all patients respond favorably to DDAVP therapy. Antifibrinolytic tablets, consisting of tranexamic acid, can stabilize blood clots by inhibiting fibrinolysis, providing extra protection in opposition to mucosal bleeding and the course of surgical processes. Individualized remedy plans, daily monitoring of component XI ranges, and close collaboration among sufferers, hematologists, and healthcare vendors are important for successfully managing factor XI deficiencies. Ongoing studies aim to enhance our knowledge of this rare illness and expand progressive remedy strategies, ultimately enhancing the lifestyles of individuals affected by component XI deficiencies.
Dyslipidemia due to non-conforming lipid profiles poses an excellent risk of heart failure (CVD) in people with diabetes. Strong control requires a complete approach that includes lifestyle qualifications and pharmacological mediation. Lifestyle adaptations, including a healthy diet and upgraded bodily avocation, play an important role in coping with dyslipidemia. Abstinence from food reduces saturated fat, trans fat, and cholesterol, integrated with extreme-fiber elements and end-three oily acids, facilitating lipid sketches. Regular upsetting increases the levels of extreme-mass lipoprotein (HDL) cholesterol, promotes a burden deficit, and aids in the dyslipidemia maneuver. While behavioral modifications are inadequate, pharmacological treatments have evolved the expected main. Statins form the cornerstone of dyslipidemia control in patients with diabetes despite standard lipid levels because of their potential to lower depressed-mass lipoprotein (LDL) cholesterol levels. Additional lipid-curbing sellers, in addition to ezetimibe, hostility acid sequestrants, and PCSK9 inhibitors, can be used in healing processes to help lipid profiles. The most recent improvements include new formulations of antidiabetic capsules that display friendly results on lipid limits in patients with diabetes. Sodium-glucose co-bearer-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) immediately offer cardiovascular approval and assist in lipid decline. SGLT-2 inhibitors decrease LDL cholesterol and triglyceride levels, concurrently with the activity of GLP-1 RAs, usually aimed at triglyceride and LDL cholesterol levels.
Pulmonary and respiratory well-being is an important area of clinical studies, especially given the increasing prevalence of breathing illnesses such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and Acute Respiratory Distress Syndrome (ARDS). Antioxidants and nutraceuticals have garnered tremendous attention for their therapeutic roles in managing these conditions. This overview evaluates the current evidence regarding the efficacy of various antioxidants and nutraceuticals, including vitamins C and E, N-acetylcysteine, omega-3 fatty acids, and polyphenols, in improving respiratory health. Antioxidants help reduce oxidative stress, a primary factor in the pathogenesis of many respiratory diseases. Nutraceuticals provide dietary strategies to support pulmonary function and reduce inflammation. Clinical studies have shown that these compounds can enhance lung function, decrease inflammation, and improve overall quality of life in patients with respiratory issues. However, results are often mixed, and more large-scale randomized controlled trials are needed to confirm their benefits. Additionally, the bioavailability and optimal dosing of these compounds remain areas of ongoing research. Despite these challenges, incorporating antioxidants and nutraceuticals into general respiratory care shows promise as a comprehensive approach to complement pharmacotherapy. This overview underscores the need for continued research into the specific mechanisms through which these compounds exert their effects, leveraging their inherent characteristics and potential to be integrated into clinical practice for the treatment of respiratory disorders.
